Anti-Vascular Endothelial Growth Factor Therapeutics Market: Industry Trends, Growth Analysis & Forecast to 2033

Anti-vascular Endothelial Growth Factor Therapeutics Market  (anti-VEGF) therapeutics have transformed the treatment of retinal diseases and certain cancers by preventing abnormal blood vessel growth. These therapies are widely used for conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), helping preserve vision and improve patient outcomes.

While anti-VEGF therapies continue to play a critical role in ophthalmology, the market is entering a new phase. The increasing availability of biosimilars, pricing pressure, and patent expirations are reshaping the competitive landscape. Although patient access is expanding, overall market revenue is expected to decline over the forecast period due to the growing adoption of cost-effective alternatives.

Key Takeaways

• The global anti-vascular endothelial growth factor therapeutics market was valued at USD 14.5 billion in 2025.
• The market is projected to decline to USD 11.8 billion by 2033, registering a CAGR of -2.7% from 2026 to 2033.
• North America dominated the market with a 66.7% revenue share in 2025.
• Eylea remained the leading product, accounting for 58.9% of the global market.
• Age-related macular degeneration (AMD) represented the largest disease segment with 52.8% market share.
• The emergence of biosimilars is significantly reducing branded drug revenues while improving patient accessibility.
• Continuous innovation in drug delivery systems and extended dosing intervals is supporting treatment effectiveness.

Market Size & Forecast

What is Driving the Anti-VEGF Therapeutics Market?

Despite the expected decline in market value, demand for anti-VEGF therapeutics remains strong due to the rising prevalence of retinal disorders, an aging global population, and improved disease awareness. Conditions such as age-related macular degeneration and diabetic retinopathy continue to require long-term treatment, supporting consistent therapy adoption.

Download a free sample copy of the Anti-vascular Endothelial Growth Factor Therapeutics Market report to understand detailed coverage and inclusions in the final report

Advancements in ophthalmic drug delivery are also improving patient outcomes. Pharmaceutical companies are developing longer-acting formulations that reduce injection frequency while maintaining treatment effectiveness, enhancing patient convenience and treatment adherence.

Healthcare organizations are further contributing through awareness campaigns promoting early diagnosis and regular eye examinations. Earlier detection increases treatment success rates and continues to support demand for anti-VEGF therapies worldwide.

Key Market Trends

The market is witnessing a major transition as biosimilar products enter global healthcare systems. These alternatives offer similar clinical outcomes at lower costs, increasing treatment accessibility while intensifying pricing competition.

Manufacturers are simultaneously investing in next-generation biologics, sustained-release formulations, and high-dose therapies that provide longer dosing intervals and improved patient compliance.

Strategic collaborations, regulatory approvals, and product portfolio diversification remain key priorities for leading pharmaceutical companies seeking to strengthen their competitive positions.

Segmentation Analysis

By Product

Eylea

Eylea dominated the market with a 58.9% revenue share in 2025. Its strong clinical efficacy, broad range of approved retinal disease indications, and expanded high-dose regimen have strengthened its position as one of the leading anti-VEGF therapies worldwide.

By Disease

Age-related Macular Degeneration (AMD)

AMD remained the largest disease segment, accounting for 52.8% of market revenue. The growing elderly population and increasing prevalence of age-related vision disorders continue to drive demand for effective anti-VEGF treatment options.

Looking for more specific insights? Customize this report to suite your business needs

Regional Analysis

North America

North America accounted for the largest market share of 66.7% in 2025. The region benefits from advanced healthcare infrastructure, high diagnosis rates, favorable reimbursement policies, and the presence of major pharmaceutical manufacturers.

United States

The U.S. remains the largest country-level market due to widespread adoption of innovative ophthalmic therapies, significant investments in retinal disease research, and strong regulatory support for advanced biologic treatments.

Competitive Landscape

The anti-vascular endothelial growth factor therapeutics market remains highly competitive as pharmaceutical companies focus on product innovation, biosimilar development, strategic partnerships, mergers, acquisitions, and geographic expansion.

While biosimilars are increasing competition and lowering treatment costs, branded manufacturers continue investing in next-generation therapies with improved efficacy, longer treatment duration, and enhanced patient convenience to maintain market leadership.

Explore Grand View Horizon to see global and regional level statistics related to the Anti-vascular Endothelial Growth Factor Therapeutics Market

Leading Companies

Major companies operating in the global anti-vascular endothelial growth factor therapeutics market include:

• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Biogen
• Pfizer, Inc.
• Coherus BioSciences, Inc.
• Amgen, Inc.
• Bausch Health Companies, Inc.
• Viatris, Inc.

Future Outlook

Although the market is forecast to decline in value, the long-term outlook for anti-VEGF therapeutics remains clinically significant. Increasing retinal disease prevalence, improved healthcare access, and continuous innovation in biologic therapies will sustain treatment demand across developed and emerging markets.

Future growth opportunities are expected to center on extended-duration therapies, novel delivery technologies, biosimilar adoption, and personalized treatment approaches that improve both patient outcomes and healthcare affordability.

Conclusion

The global anti-vascular endothelial growth factor therapeutics market is undergoing a period of transformation. While increasing biosimilar adoption is expected to reduce overall market revenue from USD 14.5 billion in 2025 to USD 11.8 billion by 2033, demand for effective retinal disease treatments remains strong. Continued advancements in biologic innovation, drug delivery technologies, and patient awareness are expected to shape the future of the market, ensuring anti-VEGF therapies remain a cornerstone of modern ophthalmic care.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments
• Extended forecast timelines for long-term planning
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…